<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35232750</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>Peripheral Neuropathy Evaluations of Patients With Prolonged Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e1146</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000001146</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES">Recovery from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection appears exponential, leaving a tail of patients reporting various long COVID symptoms including unexplained fatigue/exertional intolerance and dysautonomic and sensory concerns. Indirect evidence links long COVID to incident polyneuropathy affecting the small-fiber (sensory/autonomic) axons.</AbstractText><AbstractText Label="METHODS">We analyzed cross-sectional and longitudinal data from patients with World Health Organization (WHO)-defined long COVID without prior neuropathy history or risks who were referred for peripheral neuropathy evaluations. We captured standardized symptoms, examinations, objective neurodiagnostic test results, and outcomes, tracking participants for 1.4 years on average.</AbstractText><AbstractText Label="RESULTS">Among 17 patients (mean age 43.3 years, 69% female, 94% Caucasian, and 19% Latino), 59% had &#x2265;1 test interpretation confirming neuropathy. These included 63% (10/16) of skin biopsies, 17% (2/12) of electrodiagnostic tests and 50% (4/8) of autonomic function tests. One patient was diagnosed with critical illness axonal neuropathy and another with multifocal demyelinating neuropathy 3 weeks after mild COVID, and &#x2265;10 received small-fiber neuropathy diagnoses. Longitudinal improvement averaged 52%, although none reported complete resolution. For treatment, 65% (11/17) received immunotherapies (corticosteroids and/or IV immunoglobulins).</AbstractText><AbstractText Label="DISCUSSION">Among evaluated patients with long COVID, prolonged, often disabling, small-fiber neuropathy after mild SARS-CoV-2 was most common, beginning within 1 month of COVID-19 onset. Various evidence suggested infection-triggered immune dysregulation as a common mechanism.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oaklander</LastName><ForeName>Anne Louise</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0002-9578-1596</Identifier><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece. aloaklander@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mills</LastName><ForeName>Alexander J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toran</LastName><ForeName>Lisa S</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Bryan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dalakas</LastName><ForeName>Marinos C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nath</LastName><ForeName>Avindra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>From the Nerve Unit (A.L.O., A.J.M.), Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital, Boston, Massachusetts; Department of Neurology (M.K.), Dell Medical School, The University of Texas, Austin, Texas; Department of Neurology (L.S.T.), Confluence Health, Wenatchee; Section of Infections of the Nervous System (B.S., A.N.), National Institute of Neurological Disorders and Stroke (NINDS) at the National Institutes of Health (NIH), Bethesda, Maryland; and Neuromuscular Division (M.C.D.), Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, and National and Kapodistrian University of Athens Medical School, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS093653</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 FD007769</GrantID><Acronym>FD</Acronym><Agency>FDA HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016756">Immunoglobulins, Intravenous</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004568" MajorTopicYN="N">Electrodiagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016756" MajorTopicYN="N">Immunoglobulins, Intravenous</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010523" MajorTopicYN="N">Peripheral Nervous System Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35232750</ArticleId><ArticleId IdType="pmc">PMC8889896</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000001146</ArticleId><ArticleId IdType="pii">9/3/e1146</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization
A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. 2021. Accessed October 1, 2021. WHO/2019-nCoV/Post_COVID-19_condition/Clinical_case_definition/2021.1.</Citation></Reference><Reference><Citation>Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy: a review. JAMA Neurol. 2019;76(10):1240-1251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10021074</ArticleId><ArticleId IdType="pubmed">31498378</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al. . Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Treister R, Lodahl M, Lang M, Tworoger SS, Sawilowsky S, Oaklander AL. Initial development and validation of a patient-reported symptom survey for small-fiber polyneuropathy. J Pain. 2017;18(5):556-563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947871</ArticleId><ArticleId IdType="pubmed">28063957</ArticleId></ArticleIdList></Reference><Reference><Citation>Zirpoli G, Downs S, Farhad K, Oaklander AL. Initial validation of the Mass General neuropathy exam tool (MAGNET) for diagnosing small-fiber polyneuropathy. Ann Neurol. 2018. Proccedings of the 2018 meeting of the American Neurological Association.</Citation></Reference><Reference><Citation>Bocci T, Campiglio L, Zardoni M, et al. . Critical illness neuropathy in severe COVID-19: a case series. Neurol Sci. 2021;42(12):4893-4898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8414960</ArticleId><ArticleId IdType="pubmed">34477990</ArticleId></ArticleIdList></Reference><Reference><Citation>Lang M, Treister R, Oaklander AL. Diagnostic value of blood tests for occult causes of initially idiopathic small-fiber polyneuropathy. J Neurol. 2016;263(12):2515-2527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5845263</ArticleId><ArticleId IdType="pubmed">27730378</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X, Treister R, Lang M, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord. 2018;11:1756285617744484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5791555</ArticleId><ArticleId IdType="pubmed">29403541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bitirgen G, Korkmaz C, Zamani A, et al. . Corneal confocal microscopy identifies corneal nerve fibre loss and increased dendritic cells in patients with long COVID. Br J Ophthalmol. 2021. doi: 10.1136/bjophthalmol-2021-319450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bjophthalmol-2021-319450</ArticleId><ArticleId IdType="pmc">PMC8359871</ArticleId><ArticleId IdType="pubmed">34312122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>